Amgen To Present At The BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

On June 18, 2020 Amgen (NASDAQ: AMGN) reported that it will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference at 4:00 p.m. ET on Tuesday, June 23, 2020 (Press release, Amgen, JUN 18, 2020, View Source [SID1234561235]). Elliott Levy, senior vice president of R&D Strategy and Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


NantHealth Presented Clinical Data on Immunotherapy, Molecularly Targeted Agents and Tumor Biology at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

On June 18, 2020 NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, reported the publication of four abstracts on developmental therapeutics for immunotherapy, molecularly targeted agents and tumor biology during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 Virtual Scientific Program (Press release, NantHealth, JUN 18, 2020, View Source [SID1234561219]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program, held virtually from May 29-31, 2020, gathered oncology physicians, biotechnology executives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care.

Alongside ImmunityBio, LLC, and others, Dr. Sandeep K. Reddy, Chief Medical Officer at NantHealth, and Christopher Szeto, Director of Machine Learning at NantHealth, presented the data gathered from NantHealth’s database which was used to advance findings in developmental therapeutics.

The details of NantHealth’s ASCO (Free ASCO Whitepaper) posters are as follows:

Title: "Effect of chemokine signaling signatures on resolving discrepancy between TMB and checkpoint expression"
Authors: Saihitha Veerapaneni, Rahul Parulkar, Sandeep K. Reddy, Shahrooz Rabizadeh, Stephen Charles Benz and Christopher Szeto; ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City, CA
Abstract Number: 3131
Session Title: Developmental Therapeutics—Immunotherapy

"In this study, 1,395 clinical samples from the NantHealth database with matched tumor normal whole exomes and deep whole-transcriptomic sequencing were analyzed to confirm previous findings that Tumor Mutation Burden (TMB) and PDL1 mRNA were not correlated," said Dr. Sandeep K. Reddy, Chief Medical Officer, NantHealth. "However, chemokine activity may be an alternative to TMB and PDL1 to identify patients appropriate for immunotherapy and can help resolve discordant cases."

Title: "Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities"
Authors: Jacob J. Adashek, Christopher Szeto, J. Zack Sanborn, Sandeep K. Reddy, Amir A. Toor, Stamatina Danielides, Steven Smith, Steven R. Grossman, Charles V Clevenger, Anthony Faber, Andrea Ferreira-Gonzalez, Sosipatros Alexandros Boikos; University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; NantHealth, Culver City, CA
Abstract Number: 3576
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

"The Cancer Genome Atlas (TCGA) data for 7,087 patients and about 2,700 patients in the NantHealth database were used to identify differential patterns of checkpoint gene expression across different ethnic groups," said Dr. Sandeep K. Reddy, Chief Medical Officer, NantHealth. "White breast cancer patients might be anticipated to exhibit reduced sensitivity to PD1/CTLA4 blockade, while Black colon cancer patients may exhibit reduced sensitivity to IDO1 therapies, such as epacadostat. Ethnicity may represent a significant factor for efficacy checkpoint blockade therapies."

Title: "Highly accurate automated tissue classification using deep learning on digital pathology images: A novel tool for resolving conflicts in diagnosis"
Authors: Liudmila Beziaeva, Mustafa Jaber, Stephen Charles Benz, Shahrooz Rabizadeh, and Christopher Szeto, ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City, CA
Abstract Number: 3578
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

"NantHealth combined whole slide imaging with deep neural networks to develop a tool which can identify which of 24 primary tumor types a sample is derived from with 94.6 percent accuracy," said Christopher Szeto, Director of Machine Learning, NantHealth. "This accuracy, which approaches that of a human pathologist, is achieved by focusing machine-vision attention on just tumor regions within bulk samples. Used in conjunction with molecular profiling, rates of Cancers of Unknown Primary (CUP) or misdiagnosis can feasibly be minimized to improve patient care."

Title: "High correlation between TMB, expressed TMB, and neoantigen load using tumor: Normal whole exome DNA and matched whole transcriptome RNA sequencing"
Authors: Christopher Szeto, Mrinal M. Gounder, Rahul Parulkar, Andrew Nguyen, Shahrooz Rabizadeh, Sandeep K. Reddy; Memorial Sloan Kettering Cancer Center, New York, NY; ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City, CA
Abstract Number: e15238
Session Title: Publication Only: Developmental Therapeutics—Immunotherapy

"Surprisingly, we see minimal difference between the various biomarkers derived from mutational burden," said Christopher Szeto, Director of Machine Learning, NantHealth. "Tissue-specific TMB thresholds may be useful in patient with Sarcoma and Pancreatic cancers. Otherwise, additional data inputs such as microbiome, chemokine expression, and TME cell phenotyping may be required to improve upon TMB as a biomarker of immunotherapy response."

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

On June 18, 2020 Almac Discovery reported that it will present significant new data on their lead Oncology programmes – the next generation protein drug conjugate programme targeting ROR1 and its lead small molecule inhibitor programme targeting USP7 in poster sessions at this year’s American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, which is being held June 22-24, 2020 (Press release, Almac, JUN 18, 2020, View Source [SID1234561236]). Both programmes are advancing towards the nomination of candidate drugs, and the new data highlight significant progress that has been made in the last year towards this goal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have developed ADP-c165, a potent and selective ROR1-targeting protein drug conjugate that exploits the properties of small VNAR protein domains. This agent shows excellent efficacy in patient-derived xenograft models with complete and durable regressions observed. We are excited to share this data at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting and the potential of this novel PDC for the treatment of solid tumour indications, particularly triple-negative breast cancer," commented Graham Cotton, Head of Protein Therapeutics, Almac Discovery.

Xavier Jacq, VP Biology at Almac Discovery, said, "Using our potent and highly selective USP7 inhibitors, we have uncovered a completely novel mode of action for USP7 in modulating and reprograming the tumour microenvironment by directly impacting VEGF secretion from fibroblasts. In addition to the established modulation of the p53/MDM2 pathway in cancer cells, this important finding supports new opportunities for combining USP7 inhibitors with immune modulators. We are delighted to share our recent discovery differentiating USP7 inhibition from MDM2 antagonists at the upcoming AACR (Free AACR Whitepaper) Virtual Annual Meeting."

Details are as follows:

Title: Discovery of a novel function for USP7 inhibitors: Reprogramming the tumour microenvironment
Authors: Anamarija Jurisic, Julien Daubriac, Mark Wappett, Ian T. Lobb, Aaron Cranston, Stephanie Burton, Peggy Sung, Gerald Gavory, Colin R. O’Dowd, Tim Harrison, Xavier Jacq. Almac Discovery, Belfast, UK
Abstract Number: 8303
Session: Drug Targets in the Microenvironment
Poster Number: #6057
Type: E-poster
Date & Time: 22 June (9:00 a.m. – 6:00 p.m. EDT)

Title: Exploiting the properties of VNAR domains for the development of novel efficacious protein drug conjugates targeting the oncofetal protein ROR1
Authors: Graham Cotton, Jennifer Thom, Paul Trumper, Andrei Kamenski, Stacey Bell, Mark Wappett, Caroline Barelle, Marina Kovaleva, Alicia Campion, Elisa Persiani, Andrew Porter, Estelle McLean, Aidan McCann, Chiara Saladino, Aaron Cranston, Tim Harrison. Almac Discovery, Edinburgh, United Kingdom, Elasmogen Ltd, Aberdeen, United Kingdom, Almac Discovery, Belfast, UK
Abstract Number:2785
Session: Antibody Technologies
Poster Number: 538
Type: E-poster
Date & Time: 22 June (9:00 a.m. – 6:00 p.m. EDT)

Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351, the First Third-Generation BCR-ABL Inhibitor in China

On June 18, 2020 Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that Guangzhou Healthquest Pharma Co., Ltd, a wholly-owned subsidiary of Ascentage Pharma’s, has submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) for HQP1351 for the treatment of patients with T315I-mutant chronic phase chronic myeloid leukemia (CP-CML) and accelerated phase CML (AP-CML) (Press release, Ascentage Pharma, JUN 18, 2020, View Source [SID1234561220]). This is Ascentage Pharma’s first NDA submission since its inception. If approved, HQP1351 will become the first third-generation BCR-ABL inhibitor therapeutics in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ascentage Pharma recently engaged in pre-NDA discussions with the CDE regarding the NDA based on results from two pivotal studies in patients with T315I-mutant CP-AML and AP-CML. The CDE has agreed that the company should proceed to submit the NDA for those two indications.

CML is a hematologic malignancy of the white blood cells. BCR-ABL tyrosine kinase inhibitors (TKI) have significantly improved the clinical management of CML. However, despite clinical benefits offered by the first-generation BCR-ABL inhibitor imatinib (GLEEVEC), and several second-generation TKIs, acquired resistance to TKIs remains a major challenge in the treatment of CML. BCR-ABL tyrosine kinase mutations represent a key mechanism of acquired drug resistance; T315I, which is the most common drug-resistant mutation, occurs in about 25% of patients with drug-resistant CML. Patients with T315I-mutant CML are resistant to both first- and second-generation BCR-ABL inhibitors, hence presenting an urgent unmet medical need for effective treatment.

HQP1351 is a novel, orally active, potent third-generation BCR-ABL inhibitor designed to effectively target BCR-ABL mutants, including T315I, and the first China-developed third-generation BCR-ABL inhibitor targeting drug-resistant CML. In July 2019, HQP1351 was cleared by the US Food and Drug Administration (FDA) to enter a Phase Ib clinical study. In May 2020, HQP1351 was granted an Orphan Drug Designation and a Fast Track Designation by the US FDA.

"As Ascentage Pharma’s first NDA and one that may lead to the market authorization of the first third-generation BCR-ABL inhibitor in China, this submission marks a major milestone for our company," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. "For patients with CML who cannot be effectively treated by currently available TKIs, there remains an urgent unmet medical need for safer and more effective therapies. We hope that HQP1351 will bring a breakthrough to the current conundrum and benefit more patients."

Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti-PD-1/L1 Therapy

On June 18, 2020 Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or after anti–programmed cell death receptor or ligand (anti–PD-1/L1) therapy (Press release, Linnaeus Therapeutics, JUN 18, 2020, View Source [SID1234561237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Linnaeus is currently evaluating LNS8801 in a phase 1 clinical trial in patients with advanced cancer. The company expects to identify the recommended phase 2 dose this summer and to begin its phase 2 program evaluating LNS8801 as a monotherapy and in combination with targeted therapies in early fall.

LNS8801 is a first-in-class, orally bioavailable, small-molecule that is a highly specific and potent agonist of the G-protein estrogen receptor (GPER). GPER is widely expressed on cancers. Agonizing GPER both stops cancers from proliferating and makes them more visible to the immune system.

"Receiving Fast Track designation for LNS8801 is an important step in its clinical development as we near the end of our phase 1 dose-escalation study and advance LNS8801 into phase 2 clinical trials," said Patrick Mooney, MD, Chief Executive Officer of Linnaeus. "We are pleased that the FDA recognizes the potential of LNS8801 to help patients with melanoma who have progressed after anti–PD-1/L1 therapy."

About Fast Track Designation
Fast Track designation is a process designed to facilitate the expedited development and review of new drugs that treat serious or life-threatening conditions and that have demonstrated the potential to fill an unmet medical need. The purpose is to advance new drugs earlier for patients who need them.

A company with a drug that receives Fast Track designation is eligible for some or all of the following:

More frequent meetings with the FDA to discuss the drug’s development and ensure collection of the appropriate data needed to support drug approval
More frequent written communication from the FDA about such things as the design of the proposed clinical trials and use of biomarkers
Eligibility for Accelerated Approval and Priority Review if relevant criteria are met
Rolling Review, which means that a drug company can submit completed sections of its New Drug Application (NDA) for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. NDA review usually does not begin until the drug company has submitted the entire application to the FDA.
About LNS8801
LNS8801 is an orally bioavailable and highly specific agonist of GPER whose activity is dependent on the expression of GPER. GPER activation suppresses well-known tumor-associated genes, such as c-Myc and PD-L1. In preclinical cancer models, LNS8801 displays potent antitumor activities across a wide range of tumor types, rapidly shrinking tumors and inducing immune memory. LNS8801 monotherapy has shown significant antitumor activity, including inducing complete responses that are immune to rechallenge. LNS8801 also has shown effects when combined with targeted therapies, chemotherapies, and immunotherapies. LNS8801 is currently in a phase 1/2 clinical trial in patients with advanced cancer at six comprehensive cancer centers in the United States.